These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 24428525

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antioxidants in Huntington's disease.
    Johri A, Beal MF.
    Biochim Biophys Acta; 2012 May; 1822(5):664-74. PubMed ID: 22138129
    [Abstract] [Full Text] [Related]

  • 3. Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.
    Naia L, Ribeiro MJ, Rego AC.
    Rev Neurosci; 2011 Dec 02; 23(1):13-28. PubMed ID: 22150069
    [Abstract] [Full Text] [Related]

  • 4. Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.
    Essa MM, Moghadas M, Ba-Omar T, Walid Qoronfleh M, Guillemin GJ, Manivasagam T, Justin-Thenmozhi A, Ray B, Bhat A, Chidambaram SB, Fernandes AJ, Song BJ, Akbar M.
    Neurotox Res; 2019 Apr 02; 35(3):739-774. PubMed ID: 30632085
    [Abstract] [Full Text] [Related]

  • 5. Mitochondrial targeted antioxidants as potential therapy for huntington's disease.
    Upadhayay S, Kumar P.
    Pharmacol Rep; 2024 Aug 02; 76(4):693-713. PubMed ID: 38982016
    [Abstract] [Full Text] [Related]

  • 6. Oxidative stress is increased in C. elegans models of Huntington's disease but does not contribute to polyglutamine toxicity phenotypes.
    Machiela E, Dues DJ, Senchuk MM, Van Raamsdonk JM.
    Neurobiol Dis; 2016 Dec 02; 96():1-11. PubMed ID: 27544481
    [Abstract] [Full Text] [Related]

  • 7. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants.
    Stack EC, Matson WR, Ferrante RJ.
    Ann N Y Acad Sci; 2008 Dec 02; 1147():79-92. PubMed ID: 19076433
    [Abstract] [Full Text] [Related]

  • 8. Emerging chemotherapeutic strategies for Huntington's disease.
    Ryu H, Ferrante RJ.
    Expert Opin Emerg Drugs; 2005 May 02; 10(2):345-63. PubMed ID: 15934871
    [Abstract] [Full Text] [Related]

  • 9. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA.
    J Neurol Sci; 2005 Jun 15; 233(1-2):145-62. PubMed ID: 15896810
    [Abstract] [Full Text] [Related]

  • 10. Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine.
    Ribeiro M, Silva AC, Rodrigues J, Naia L, Rego AC.
    Toxicol Sci; 2013 Dec 15; 136(2):487-99. PubMed ID: 24008831
    [Abstract] [Full Text] [Related]

  • 11. Oxidative Stress and Antioxidants in Neurological Diseases: Is There Still Hope?
    Carvalho AN, Firuzi O, Gama MJ, Horssen JV, Saso L.
    Curr Drug Targets; 2017 Mar 30; 18(6):705-718. PubMed ID: 27033198
    [Abstract] [Full Text] [Related]

  • 12. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC, Chen HM, Chen YC, Chang CP, Chang C, Chern Y.
    Biochim Biophys Acta; 2014 Sep 30; 1842(9):1668-80. PubMed ID: 24946181
    [Abstract] [Full Text] [Related]

  • 13. Time-Course Analysis of Protein and Lipid Oxidation in the Brains of Yac128 Huntington's Disease Transgenic Mice.
    Brocardo PS, McGinnis E, Christie BR, Gil-Mohapel J.
    Rejuvenation Res; 2016 Apr 30; 19(2):140-8. PubMed ID: 26371883
    [Abstract] [Full Text] [Related]

  • 14. Protective effects of 3-alkyl luteolin derivatives are mediated by Nrf2 transcriptional activity and decreased oxidative stress in Huntington's disease mouse striatal cells.
    Oliveira AM, Cardoso SM, Ribeiro M, Seixas RS, Silva AM, Rego AC.
    Neurochem Int; 2015 Dec 30; 91():1-12. PubMed ID: 26476055
    [Abstract] [Full Text] [Related]

  • 15. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
    Bates GP, Hockly E.
    Curr Opin Neurol; 2003 Aug 30; 16(4):465-70. PubMed ID: 12869804
    [Abstract] [Full Text] [Related]

  • 16. Reagents that block neuronal death from Huntington's disease also curb oxidative stress.
    Valencia A, Sapp E, Reeves PB, Alexander J, Masso N, Li X, Kegel KB, DiFiglia M.
    Neuroreport; 2012 Jan 04; 23(1):10-5. PubMed ID: 22045254
    [Abstract] [Full Text] [Related]

  • 17. Mitochondrial Dysfunction in Huntington's Disease: Pathogenesis and Therapeutic Opportunities.
    Sharma A, Behl T, Sharma L, Aelya L, Bungau S.
    Curr Drug Targets; 2021 Jan 04; 22(14):1637-1667. PubMed ID: 33655829
    [Abstract] [Full Text] [Related]

  • 18. Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.
    Velusamy T, Panneerselvam AS, Purushottam M, Anusuyadevi M, Pal PK, Jain S, Essa MM, Guillemin GJ, Kandasamy M.
    Oxid Med Cell Longev; 2017 Jan 04; 2017():3279061. PubMed ID: 28168008
    [Abstract] [Full Text] [Related]

  • 19. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases.
    Singh A, Kukreti R, Saso L, Kukreti S.
    Molecules; 2019 Apr 22; 24(8):. PubMed ID: 31013638
    [Abstract] [Full Text] [Related]

  • 20. The therapeutic role of creatine in Huntington's disease.
    Ryu H, Rosas HD, Hersch SM, Ferrante RJ.
    Pharmacol Ther; 2005 Nov 22; 108(2):193-207. PubMed ID: 16055197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.